The Danish Competition Appeals Tribunal upholds decision fining a company for excessive pricing (CD Pharma)

On 29 November 2018, the Danish Competition Appeals Tribunal upheld a 31 January 2018 decision of the Danish Competition Authority (“DCA”) finding that CD Pharma abused its dominant position on the Danish market by charging excessive prices for the sale of oxytocin, a hormone that acts as a neurotransmitter in the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Tim Kasten, The Danish Competition Appeals Tribunal upholds decision fining a company for excessive pricing (CD Pharma), 29 November 2018, e-Competitions Bulletin November 2018, Art. N° 88967

Visites 169

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues